Tofersen (Qalsody), an ASO, targets mutant SOD1 mRNA in ALS, and Milasen, a compassionate-use ASO, was developed for Batten disease (CLN7 variant). This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.